Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Sells $13,440.16 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Joshua Pinto sold 8,048 shares of Neumora Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $1.67, for a total value of $13,440.16. Following the completion of the sale, the president now directly owns 76,952 shares of the company’s stock, valued at approximately $128,509.84. This trade represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Neumora Therapeutics Price Performance

NASDAQ NMRA opened at $1.80 on Friday. Neumora Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $21.00. The stock has a market capitalization of $290.81 million, a PE ratio of -0.96 and a beta of 2.50. The company’s 50 day simple moving average is $4.30 and its two-hundred day simple moving average is $9.31.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on NMRA shares. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a report on Friday, February 14th. Bank of America decreased their price objective on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a report on Monday, January 6th. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. William Blair reissued an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Finally, Royal Bank of Canada downgraded shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $29.00 to $4.00 in a report on Thursday, January 2nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Institutional Trading of Neumora Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of NMRA. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Neumora Therapeutics in the 4th quarter worth approximately $61,000. PNC Financial Services Group Inc. purchased a new stake in Neumora Therapeutics in the 4th quarter worth approximately $64,000. Quantbot Technologies LP purchased a new stake in Neumora Therapeutics in the 4th quarter worth approximately $92,000. PEAK6 LLC purchased a new stake in shares of Neumora Therapeutics during the 4th quarter valued at $117,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Neumora Therapeutics during the 4th quarter valued at $135,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.